PMID- 10704623
OWN - NLM
STAT- MEDLINE
DCOM- 20000502
LR  - 20190718
IS  - 0021-9150 (Print)
IS  - 0021-9150 (Linking)
VI  - 149
IP  - 1
DP  - 2000 Mar
TI  - Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels.
PG  - 123-9
AB  - Data pooled from 21 atorvastatin clinical trials have been analyzed to establish 
      the safety of reducing low density lipoprotein cholesterol (LDL-C) levels below 
      currently recommended minimum targets in hypercholesterolemic patients. Safety 
      data for atorvastatin-treated patients with at least one LDL-C value < or =80 
      mg/dl (2.1 mmol/l) (n = 319) during treatment (mean LDL-C level throughout 
      treatment was 91 mg/dl [2.4 mmol/l]) were compared to those from all 
      atorvastatin-treated patients (n = 2502) and patients treated with lovastatin, 
      simvastatin or pravastatin (n = 742). The frequency of treatment-associated 
      adverse events (AEs) in the atorvastatin LDL-C < or =80 mg/dl (2.1 mmol/l) 
      subgroup (24%) was comparable to the frequencies observed for all 
      atorvastatin-treated patients (20%) and for patients receiving the other statins 
      (24%). Patient withdrawals due to treatment-associated AEs (constipation, 
      dyspepsia and flatulence being the most common) were consistent and low across 
      treatment groups. No treatment-associated deaths occurred in any group. Safety 
      data for 21 atorvastatin-treated patients with LDL-C < or =50 mg/dl (1.3 mmol/l) 
      were also analyzed and found to be similar to all atorvastatin-treated patients 
      and patients treated with the other statins. While recognizing the short-term 
      nature of the data (all patients who received atorvastatin were treated for < or 
      =1 year and approximately 30% were treated for < or =6 months), this analysis 
      suggests that reducing LDL-C levels below 80 (2.1 mmol/l) or 50 mg/dl (1.3 
      mmol/l) with atorvastatin does not alter its safety profile, as measured by 
      frequency of AEs, which remains similar to those of other statins.
FAU - Bakker-Arkema, R G
AU  - Bakker-Arkema RG
AD  - Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, 2800 
      Plymouth Road, Ann Arbor, MI 48105-1047, USA.
FAU - Nawrocki, J W
AU  - Nawrocki JW
FAU - Black, D M
AU  - Black DM
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PL  - Ireland
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Heptanoic Acids)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (Pyrroles)
RN  - 9LHU78OQFD (Lovastatin)
RN  - A0JWA85V8F (Atorvastatin)
RN  - AGG2FN16EV (Simvastatin)
RN  - KXO2KT9N0G (Pravastatin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticholesteremic Agents/*administration & dosage/*adverse effects
MH  - Atorvastatin
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Heptanoic Acids/*administration & dosage/*adverse effects
MH  - Humans
MH  - Hypercholesterolemia/diagnosis/*drug therapy
MH  - Lipoproteins, LDL/analysis/*drug effects
MH  - Lovastatin/administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Pravastatin/administration & dosage
MH  - Pyrroles/*administration & dosage/*adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - Severity of Illness Index
MH  - Simvastatin/administration & dosage
MH  - Treatment Outcome
EDAT- 2000/03/08 09:00
MHDA- 2000/05/08 09:00
CRDT- 2000/03/08 09:00
PHST- 2000/03/08 09:00 [pubmed]
PHST- 2000/05/08 09:00 [medline]
PHST- 2000/03/08 09:00 [entrez]
AID - S0021-9150(99)00294-4 [pii]
AID - 10.1016/s0021-9150(99)00294-4 [doi]
PST - ppublish
SO  - Atherosclerosis. 2000 Mar;149(1):123-9. doi: 10.1016/s0021-9150(99)00294-4.